Key Points
- 2026 is shaping up as a make-or-break transition year for the Danish drug giant, with big pricing pressures and looming patent expirations in Brazil, Canada, and China.
- The company is coming off a brutal year of volatility and a sinking stock price — its worst since listing in Copenhagen over 30 years ago.
- The U.S. market remains the ultimate proving ground, analysts say, and investors are watching closely.
Novo Nordisk’s fall from Wall Street favorite to major laggard has set the tone for a tense 2026, as the weight-loss drug powerhouse scrambles to rebuild investor trust and stabilize its blockbuster business.
After suffering its worst stock performance in company history, Novo faced a long list of setbacks: multiple guidance cuts, rapid advances from rival Eli Lilly, leadership turmoil, and a surge of cheaper copycat drugs crowding the U.S. market.
But just days before 2026 kicked off, Novo scored a badly needed win — the FDA approved its new Wegovy weight-loss pill, making it the first oral GLP-1 treatment officially cleared for obesity. The news sent shares jumping nearly 10%, with investors suddenly hopeful that Novo might slow Eli Lilly’s momentum.
Analysts called it an early “Christmas present” — and it symbolizes everything Novo now has riding on 2026.
From Injections to Pills: A Big Strategic Bet
Being first to deliver a pill may help Novo recover ground after losing serious territory in the GLP-1 race. Analysts widely agree that the approval is a major milestone, even though many expected it.
Eli Lilly is expected to win approval for its own oral drug, orforglipron, no later than mid-2026 — setting up a fierce battle.
Novo says the pill form of Wegovy offers similar effectiveness to its injectable version, with patients losing an average of 16.6% of body weight in 64 weeks, vs Eli Lilly’s orforglipron at 12.4% in 72 weeks.
Beyond performance, pills are simply easier for consumers:
✔ No needles
✔ No refrigeration
✔ Easier to distribute globally
✔ Easier to adopt
And consumers overwhelmingly prefer pills — a huge advantage in a market driven by convenience.
Can Novo Change the Story?
Eli Lilly’s Zepbound has dominated headlines as the best weekly injection on the market, capturing massive market share.
Novo has taken a different angle, highlighting obesity as a disease, not just a weight-loss journey — pointing out Wegovy’s benefits for heart, liver, and kidney health. Scientifically impressive, sure. But analysts say that’s not what U.S. consumers care about.
Americans want one thing:
👉 Maximum weight loss potential.
Trials of Novo’s proposed higher 7.2 mg Wegovy dose show an average 20.7% weight drop, almost matching Zepbound. If approved, that could change the narrative in Novo’s favor.
“If Novo can plug into that ‘maximum results’ story with the Wegovy pill, they could be in a strong position,” analysts say.
The U.S. Consumer Is Now in the Driver’s Seat
Unlike many blockbuster drugs, the obesity market is heavily consumer-driven, not just insurance-driven.
But politics just reshaped the battlefield.
President Donald Trump’s return to the White House has brought intense pressure on drugmakers. He’s promised tariffs, demanded lower drug prices, and criticized U.S. price gouging compared to Europe.
Ultimately, the administration struck a deal with Novo and Lilly to:
- Lower Medicare and Medicaid pricing
- Offer discounted drugs directly to consumers
- Launch TrumpRx.gov, a new discount platform debuting January 2026
At the same time, cheap compounders remain a serious threat, still attracting customers who want lower-cost alternatives.
Morningstar analysts say TrumpRx helps Novo compete — but Lilly may still hit the market faster with its pill, giving it a critical edge.
Leadership Chaos and “Show Me” Pressure
Investors are also waiting to see whether Novo’s new leadership can actually execute.
2025 brought dramatic boardroom drama:
- CEO ousted after eight years
- Entire independent board resigned months later
- Disputes over strategy and U.S. handling spilled into public view
Analysts now say the U.S. market is a “show me” situation. No more promises. Investors want real traction — and they don’t see it yet.
Meanwhile, Novo faces:
- Lower pricing pressure thanks to MFN policies
- Patent losses in multiple countries
- A likely hit to revenues
- Competition heating up globally
And that’s before mentioning the next wave of competition: Pfizer, Amgen, AstraZeneca, Roche, and more are accelerating late-stage obesity drugs.
The Road Ahead
Beyond Wegovy, Novo has another potential blockbuster in development: CagriSema, a dual-action drug combining semaglutide with cagrilintide. More clarity is expected in 2026.
Analysts expect the weight-loss industry to evolve fast:
More drug options.
Better safety profiles.
More multi-hormone treatments.
Tougher pricing environments.
Higher consumer expectations.
Novo has also been criticized for inconsistent strategic moves, including chaotic deal talks and walk-backs, which haven’t exactly reassured Wall Street.
That’s why the Wegovy pill approval is such a symbolic turning point.
After a year of disappointments, Novo finally has a win.
Now it has to prove it can capitalize on it.
Execution is everything.
Wall Street Ends the Year With a Bang: S&P 500 Smashes Records as Santa Rally Hopes Rise
